Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →
CLEATUS
Get CLEATUS

Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)

Open
PAR-28-056Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Cancer Institute is soliciting applications for Research Units as part of the Pancreatic Cancer Detection Consortium to advance the early detection of pancreatic ductal adenocarcinoma and the characterization of precursor lesions. These multi-disciplinary teams will focus on developing and testing molecular and imaging biomarkers to identify high-risk patients and those with lesions likely to progress to cancer. Key research activities include the use of machine learning for biomarker discovery, conducting validation studies, and collecting longitudinal biospecimens for a centralized biorepository. Under solicitation PAR-28-056, the selected Research Units are required to engage in collaborative efforts, sharing data and biospecimens across the consortium. The initiative aligns with the NCI's scientific framework for pancreatic cancer by prioritizing the identification of patients who could benefit from early intervention based on genetic factors, family history, or existing precursor lesions. Applications for this federal opportunity are due by November 6, 2029.

General Info

NCI seeks research units for pancreatic cancer early detection biomarkers by November 6, 2029.

Agency

National Institutes Of Health → National Cancer Institute

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseSolicitation
Posted

Solicitation

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyNational Institutes Of Health → National Cancer Institute
ContactsNo contacts available
OfficeUSA
Organization / AgencyNational Institutes Of Health → National Cancer Institute
Office AddressUSA
ContactsNo contact information available

Full Description

Show more
Through this Notice of Funding Opportunity (NOFO), NCI solicits applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the NCI's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma (PDAC). The PCDC will support research for the development and testing of new molecular and imaging biomarkers for detecting PDAC early and for identifying patients at high risk of PDAC (because of genetic factors, family history and/or the presence of precursor lesions) who could be candidates for early intervention. The PCDC-RUs will consist of multi-disciplinary teams and will undertake studies to: identify and test biomarkers measurable in bodily fluids for early detection of PDAC and/or its precursor lesions; develop molecular- and/or imaging-based markers of pancreatic cysts and determine which lesions are likely to progress to cancer; develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC; use machine learning and computational approaches towards biomarker discovery and/or validation; and conduct biomarker validation studies. The PCDC-RUs will also collect longitudinal biospecimens for building a biorepository. Each PCDC-RU is expected to participate in collaborative activities with other PCDC-RUs and share ideas, biospecimens, and data within the Consortium.

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
High-Containment Laboratory & Scientific Research ServicesThis subcontract opportunity, titled High-Containment Laboratory and Scientific Research Services, supports the National Institutes of Health Olao under the Department of Health and Human Services. The project focuses on the NIH STEAM program, requiring the provision of specialized scientific personnel to perform basic, translational, and clinical research, as well as laboratory services and scientific computing. Work is primarily based in Bethesda and involves critical operations within BSL-1 through BSL-4 and ABSL-1 through ABSL-4 containment environments. Qualified providers must demonstrate a proven capability to operate within these high-containment facilities and deliver expert research execution and animal-care roles. This opportunity is designated as a partial Small Business Set Aside under NAICS code 541714. The solicitation was posted on November 10, 2026, with a response deadline of November 17, 2026.
National Institutes Of Health Olao

POSTED

1 day ago

DEADLINE

in 6 days
View Details
NAICS: 541714
New
Federal
Pre-solicitation Notice: On-Ramp for the Department of Defense OMNIBUS IV Multiple-Award Contract
Solicitation # HT942627RE002
The Defense Health Agency Contracting Activity intends to issue a Request for Proposal in early November 2026 for an on-ramp to the OMNIBUS IV Multiple Award, Indefinite Delivery, Indefinite Quantity contract vehicle. This opportunity is specifically set aside for small businesses certified under the Small Business Administration 8(a) Program and will focus on providing military medical research and development services. Multiple new awards are expected, all of which will align with the existing unrestricted contract vehicle. The OMNIBUS IV vehicle operates with a cumulative ceiling of 10 billion dollars and a performance period extending through June 19, 2032, including option years. To date, the contract has seen over 690 million dollars awarded across 61 task orders to various end users, including the Naval Supply Systems Command and the Uniformed Services University of the Health Sciences. Task orders may be competed via fair opportunity or through specific exceptions such as small business set-asides.
Defense Health Agency

POSTED

2 days ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Federal
DNA Sequencing Service
Solicitation # PCA-NIEHS-00080
The National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health, is conducting a market survey via a Sources Sought notice for an indefinite-delivery indefinite-quantity (IDIQ) contract to provide DNA sequencing services and associated bioinformatics support. The anticipated five-year period of performance involves processing an estimated 2,000 to 3,000 samples per month, including yeast colonies, plasmid DNA, and PCR-generated samples from human and rodent species. While high-throughput whole-plasmid sequencing is required for a small volume, Sanger sequencing will be the primary method. The contractor must ensure a Phred-equivalent quality score greater than 20 within the reportable region, with an average target region size of 700 to 1,000 base pairs. The selected provider will be responsible for providing all sample collection materials, prepaid shipping containers, and maintaining sample retention for at least 180 days. Deliverables must be provided in specific formats, including .ab1, .seq, .scf, .phd.1, .txt, and .fasta/.fa, with turnaround times of two business days for plasmid DNA or PCR amplicon samples and five business days for genomic DNA requiring PCR amplification. The government is specifically seeking capability statements from small businesses, including 8(a), SDB, WOSB, HUBZone, and VOSB concerns, to determine the appropriate acquisition method. Responses must be submitted by November 12, 2026, and include a capability statement not exceeding seven pages, along with the entity's UEI, TIN, and business size certification.
National Institutes Of Health Olao

POSTED

2 days ago

DEADLINE

in about 23 hours
View Details
NAICS: 541714
New
SBIR / STTR
USDA SBIR/STTR Topic 8.2 — Plant Production and Protection - Biology
Solicitation # USDA-NIFA-TOPIC-8.2
The USDA National Institute of Food and Agriculture is soliciting proposals under Topic 8.2 for Plant Production and Protection - Biology. This initiative focuses on advancing crop production and protection through the development of innovative plant breeding methods, diagnostic technologies for diseases, and the creation of new food and non-food crop plants. Research efforts are directed toward improving plant characteristics to mitigate biotic and abiotic stresses, developing new genotypes for commercial applications, and creating tools to support the health of natural and domesticated pollinators. This opportunity is a total small business set-aside under the SBIR/STTR mandate, restricting eligibility to companies with fewer than 500 employees. Managed by the United States Department of Agriculture, the program is led by Dr. Christopher Philips. Interested parties can find further details and application guidelines through the NIFA website.
National Institute of Food and Agriculture

POSTED

3 days ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Federal
BWA Identification Core & Assay DevelopmentThe BWA Identification Core and Assay Development subcontract, managed under the Department of Defense agency W6QK Acc-Apg, focuses on the creation and supply of core biological detection technology and assays for U.S. Navy EMBD IDS projects. The primary objective is to develop assays capable of identifying toxins, viruses, and bacteria with sensitivity and specificity levels that match laboratory PCR standards. To ensure accuracy, the project utilizes biological agent panels and simulants during the testing phase. The scope of work requires the delivery of a biological detection engine, specialized assay kits, and comprehensive performance data. This effort is categorized under NAICS code 541714 and is slated for performance in Gunpowder. The solicitation was posted on November 6, 2026, with a response deadline set for December 7, 2026.
W6QK Acc-Apg

POSTED

5 days ago

DEADLINE

in 26 days
View Details
NAICS: 541714
New
Federal
Firefox
Solicitation # DARPA-PS-26-137
The Firefox program, managed by the DARPA Biological Technologies Office, is a 36-month, three-phase initiative seeking to develop a 100-channel, non-invasive brain-computer interface with 50-micron spatial and 100-microsecond temporal resolution. The program focuses on two primary technical hurdles: the creation of components for dynamic rastering and scanning of coherent optical signals to target multiple regions of interest, and the development of non-digital data processing architectures capable of handling high data rates and computational burdens. Multiple awards are anticipated, with funding ranging between 4 million and 7 million dollars per award. Awards will be issued as Other Transaction for Prototype agreements under 10 U.S.C. 4022, utilizing a milestone-based payment schedule. The selection process is multi-staged, beginning with an abstract evaluation based on technical comprehension, technical ability, and budget realism, followed by an Oral Presentation Proposal for selected candidates. Proposers must be registered in the System for Award Management and possess a Unique Entity Identifier. Key compliance requirements include adherence to ANSI laser safety limits for human tissue exposure, Cybersecurity Maturity Model Certification, and strict guidelines regarding organizational conflicts of interest and foreign influence risk assessments.
Defense Advanced Research Projects Agcy

POSTED

5 days ago

DEADLINE

in 19 days
View Details
NAICS: 541714
New
Federal
Future Program: Laguna
Solicitation # DARPA-SN-27-15
Special Notice DARPA-SN-27-15, issued by the Defense Advanced Research Projects Agency Biological Technologies Office, serves as a public notification for the forthcoming Laguna program. This notice is intended for information and program planning purposes and does not constitute a formal solicitation for proposals. The program is anticipated to be a 36-month effort focused on the development and demonstration of defense-relevant specialty products formulated from U.S.-produced raw materials. These products must meet or exceed the critical performance requirements of existing military materials. Key deliverables for the program include predictive tools for material properties, life cycle assessments, technoeconomic analyses, and commercialization strategy plans. The primary point of contact for the initiative is Dr. William Mounfield. While this notice provides an overview of research interests, DARPA will not accept submissions at this time. Formal solicitation details and submission instructions will be posted on sam.gov upon release. All communications regarding this notice must remain unclassified.
Defense Advanced Research Projects Agcy

POSTED

6 days ago

DEADLINE

in 19 days
View Details
NAICS: 541714
New
Grant
Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed)The National Institutes of Health is seeking research projects to investigate the initiation and early progression of Type 1 Diabetes using human-relevant New Approach Methodologies. Utilizing human cells, tissues, organoids, and microphysiological systems, the initiative aims to identify early biomarkers and therapeutic targets to prevent significant pancreatic beta cell loss. This effort focuses on combining innovative experimental and computational approaches to uncover the cellular and molecular mechanisms driving the disease. Selected awardees will join the Human Islet Research Network to foster collaboration, share data and tools, and coordinate the use of limited human pancreatic tissues. With total program funding of 12 million dollars and an expected 12 awards, the project is scheduled to begin around November 1, 2027. The overarching goal is to accelerate the translation of research discoveries into practical preventive and treatment strategies through a harmonized, multi-laboratory effort.
National Institutes Of Health

POSTED

6 days ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Grant
Cooperative Agreement for affiliated Partner with Rocky Mountain Cooperative Ecosystem Studies Unit
Solicitation # G27AS00062
The U.S. Geological Survey is seeking a partner within the Rocky Mountain Cooperative Ecosystem Studies Unit to establish a cooperative agreement for research aimed at improving Chronic Wasting Disease surveillance. The project focuses on developing a robust, automated, and reproducible analytical pipeline to standardize Real-Time Quaking Induced Conversion assay data analysis, reducing the reliance on subjective interpretation. Key deliverables include the creation of machine-learning models using LSTM, CNN-LSTM, or hybrid architectures to classify fluorescence curves, the development of an open-source application via R-Shiny or Streamlit/Python for data ingestion and visualization, cross-laboratory validation across at least three independent facilities, and a peer-reviewed publication. The total program funding is estimated at 145,220 dollars for a single award, with an anticipated period of performance from April 1, 2027, to March 31, 2032. Applications must be submitted through grants.gov by December 8, 2026, and are evaluated based on purpose and relevance, technical approach, qualifications and past performance, and budget clarity. Recipients must comply with Department of the Interior general terms, geospatial data standards under the Geospatial Data Act of 2018, and federal regulations regarding financial reporting and conflict of interest. Required submission documents include a Project Abstract Summary, Biographical Sketches, and Current and Pending Support forms for all senior key personnel.
US Geological Survey

POSTED

6 days ago

DEADLINE

in 27 days
View Details
NAICS: 541714
New
Grant
Cooperative Agreement for affiliated Partner with Gulf Coast Cooperative Ecosystem Studies Unit
Solicitation # G27AS00064
The U.S. Geological Survey Eastern Ecological Science Center is soliciting applications for a Cooperative Agreement under the Gulf Coast Cooperative Ecosystem Studies Unit to perform bioinformatic analysis on avian microbiome metatranscriptomic datasets. The research focuses on genome assembly-based identification of viruses, prokaryotic, and eukaryotic microorganisms, with a specific emphasis on zoonotic and wildlife pathogens. Awardees will analyze shotgun metatranscriptomic data to estimate microbial diversity and abundance across various host species, tissues, and geographic regions, while developing reproducible bioinformatic workflows. Key requirements include collaborating on peer-reviewed publications and making data products publicly available through repositories like ScienceBase or the National Center for Biotechnology Information. The solicitation, numbered G27AS00064, has a total program funding ceiling of 459,000 dollars for one expected award. The anticipated period of performance runs from April 1, 2027, to March 31, 2030, with applications due via grants.gov by December 7, 2026. Proposals are evaluated based on purpose and relevance, technical approach, qualifications and past performance, and budget clarity. Applicants must be registered in SAM.gov and provide specific documentation, including a Project Abstract Summary, Biographical Sketches, and Current and Pending Support forms for key personnel. All geospatial data produced must adhere to Federal Geospatial Data Committee standards and the Geospatial Data Act of 2018.
US Geological Survey

POSTED

6 days ago

DEADLINE

in about 2 months
View Details
NAICS: 541714
SBIR / STTR
Specialized Bio-Research / Protocol Compliance ConsultantThis subcontract opportunity is for a Specialized Bio-Research / Protocol Compliance Consultant to support research and development projects for the United States Navy and Marine Corps Systems Command. The selected provider will conduct research involving recombinant DNA and human or animal subjects, ensuring all activities are executed according to strict research protocols. Key responsibilities include managing recombinant DNA activities within laboratory facilities and maintaining full compliance with federal, state, and local environmental laws regarding the handling of toxic materials. All work must be performed under the necessary IRB and IACUC approvals, with the final deliverables consisting of experimental data and feasibility reports. The contract is designated as a Total Small Business Set-Aside under NAICS code 541714, specifically targeting firms with fewer than 500 employees in alignment with SBIR/STTR mandates. Interested parties must submit their responses by December 2, 2026. This role is critical for prime contractors requiring specialized expertise in bio-research compliance and the technical execution of complex laboratory protocols within the Department of Defense framework.
United States Navy

POSTED

7 days ago

DEADLINE

in 21 days
View Details
NAICS: 541714
SBIR / STTR
Biolab Mirror: Artificial Intelligence / Machine Learning (AI/ML) Digital Twin for Intent Characterization and Bio-Containment Integrity
Solicitation # DTR27TZ02-NV001
The Defense Threat Reduction Agency, under the Department of War, is soliciting proposals for the Biolab Mirror, an AI/ML-driven Digital Twin designed to ensure bio-containment integrity and characterize intent in state-sponsored biological research facilities. The project implements a Physics-to-Mesh Zero Trust architecture that cross-validates digital telemetry from LIMS, SCADA, and BMS logs against unalterable physical and biological laws, such as thermodynamics and metabolic rates. This system aims to detect clandestine pathogen scaling and containment spoofing by identifying coherence failures. Beyond its defensive application, the Biolab Mirror will serve as a cyber-physical sandbox for simulating multi-domain attacks against high-containment infrastructure, filling a critical gap in current cyber-range emulation. This is a phased STTR program with a total small business set-aside. Phase I focuses on delivering a conceptual architecture and a working software prototype, while Phase II, with a ceiling price of 1.5 million dollars, involves full project effort over a 24-month duration. Proposals are evaluated based on technical merit, investigator qualifications, and commercial potential. Applicants must be registered in SAM and the SBA Company Registry. Compliance requirements include CMMC standards for safeguarding controlled unclassified information and strict adherence to organizational conflict of interest disclosures. Proposals must be submitted via the DSIP portal by January 6, 2026.
Defense Threat Reduction Agency

POSTED

7 days ago

DEADLINE

in about 2 months
View Details

More opportunities from National Institutes Of Health → National Cancer Institute

Same awarding agency

NAICS: 541715
Grant
NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)
Solicitation # PAR-28-063
The National Cancer Institute is offering the Research Specialist Award (R50) under solicitation PAR-28-063 to support exceptional clinician scientists involved in NCI-funded clinical trials research. This award aims to create stable career paths for professionals who provide leadership in developing national clinical trials, implementing these trials within their own institutions, and serving on scientific review or monitoring committees. The program is specifically designed for those who wish to maintain a high level of influence and service within NCI clinical trials networks without serving as principal investigators on research project grants. By providing dedicated salary support and increased professional autonomy, the award ensures that these vital clinician scientists are not solely dependent on external funding or grants held by other individuals. This initiative is intended to sustain the overall NCI clinical trials enterprise by securing the continuity of experienced research careers. Applications for this federal opportunity are open until February 21, 2029.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

9 days ago

DEADLINE

in over 2 years
View Details
NAICS: 541714
Grant
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
Solicitation # PAR-28-042
The National Cancer Institute, under the National Institutes of Health, has issued solicitation PAR-28-042 to provide funding for the analytical and clinical validation of biomarkers and assays related to cancer. This initiative focuses on molecular, cellular, and imaging markers used for detection, diagnosis, prognosis, treatment response, prevention, and toxicity monitoring. The goal is to support laboratory optimization and validation for assays using human samples that address specific clinical needs and intended uses. Eligible projects may utilize either a standalone UH3 mechanism or a phased UH2/UH3 approach, though clinical trials are explicitly not allowed. The solicitation was posted on November 3, 2026, with a response deadline set for November 17, 2029.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

9 days ago

DEADLINE

in about 3 years
View Details
NAICS: 923120
Grant
Notice of Change: Grants Administration Information added for NCI's Participation on PA-27-036, NIH Research Education Program - Research Experiences (Parent R25 - Clinical Trial Not Allowed)
Solicitation # NOT-CA-26-019
This Notice of Change, identified by solicitation number NOT-CA-26-019, updates the NIH Research Education Program - Research Experiences (Parent R25 - Clinical Trial Not Allowed) under PA-27-036. The primary purpose of this amendment is to incorporate specific Grants Administration Information regarding the National Cancer Institute's participation in the program. The update specifically modifies Section VII, Agency Contacts, to include the Office of Grants Administration for the National Cancer Institute as a financial and grants management contact. No other changes have been made to the original PA-27-036 guidelines. Interested parties can coordinate with the Center for Cancer Training or the Office of Grants Administration for further inquiries.
Administration of Public Health Programs

POSTED

22 days ago

DEADLINE

N/A
View Details
NAICS: 621991
Grant
Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)
Solicitation # RFA-CA-28-004
The National Cancer Institute is issuing a limited competition Notice of Funding Opportunity, solicitation RFA-CA-28-004, to support the continuation of two critical biospecimen banking resources. These resources include the National Clinical Trials Network Biobanks, which support the NCTN and the Community Oncology Research Program, and the Early-Phase and Experimental Clinical Trials Biospecimen Bank, which supports the ETCTN and other early-phase experimental trials. The primary objective is to maintain national infrastructure for the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens to enable translational cancer research, biomarker development, and the study of drug response and resistance. Eligible organizations must submit applications by February 12, 2027, to be considered for funding. All submissions will undergo a standard NIH peer-review process, and only meritorious applications will be selected. These banks are essential for linking biospecimens to clinical outcome data from large multi-site trials and supporting the development of novel cancer therapies through pharmacokinetic and pharmacodynamic analyses.
Blood and Organ Banks

POSTED

28 days ago

DEADLINE

in 3 months
View Details
NAICS: 541714
Grant
Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional)
Solicitation # PAR-28-014
The National Cancer Institute, under the National Institutes of Health, is soliciting applications for solicitation PAR-28-014 to investigate the causes and biological mechanisms of sporadic non-hereditary early-onset cancers in adults aged 18 to 49. The primary goal of this initiative is to understand the rising incidence of these cancers to improve prevention and control strategies. Research should specifically target environmental or lifestyle drivers across various demographics, the biological host responses involved, or the development of more effective methods for identifying high-risk individuals. This funding opportunity supports both standard research projects and exploratory or developmental studies through a grant award instrument, with clinical trials being optional. Interested parties must submit their applications by the deadline of October 12, 2029.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

29 days ago

DEADLINE

in almost 3 years
View Details
NAICS: 541714
Grant
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)
Solicitation # PAR-28-022
The National Cancer Institute, potentially in collaboration with the National Institute of Dental and Craniofacial Research, is soliciting applications for P50 Research Center Grants for Specialized Programs of Research Excellence. This program supports investigator-initiated translational research focused on the prevention, early detection, diagnosis, and treatment of organ-specific cancers or closely related cancer groups. Eligible research must be grounded in human biology using genetic, molecular, biochemical, structural, or cellular experimental approaches and must achieve a translational human endpoint within the grant period. Under solicitation number PAR-28-022, this opportunity covers the years 2027, 2028, and 2029 and requires the inclusion of clinical trials. The notice was posted on October 14, 2026, with a final response deadline of September 26, 2029. This initiative serves as a re-issuance of PAR-23-284 to continue funding state-of-the-art research aimed at improving clinical outcomes for cancer patients.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

29 days ago

DEADLINE

in almost 3 years
View Details
NAICS: 541715
Grant
Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)
Solicitation # RFA-CA-28-013
The National Cancer Institute, under the National Institutes of Health, is seeking meritorious proposals for the Carcinogen Hazard Assessment Monographs Program (CHAMP) Initiative. This solicitation, identified as RFA-CA-28-013, aims to fund projects that critically and systematically evaluate scientific evidence regarding carcinogenic hazards to humans to better inform cancer research, control, and prevention efforts. Interested applicants must submit their proposals by the response deadline of February 10, 2027. This opportunity is categorized as an R01 grant, and it is explicitly noted that clinical trials are not allowed under this specific funding program.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

about 1 month ago

DEADLINE

in 3 months
View Details
NAICS: 541714
Grant
Notice of Change in Application Due Date for RFA-CA-27-005 "Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)"
Solicitation # NOT-CA-26-020
This notice issued by the National Cancer Institute of the National Institutes of Health serves to amend the application timeline for the Glioblastoma Therapeutics Network clinical trial solicitation, RFA-CA-27-005. The primary modification is the addition of a second application due date on January 11, 2027, for new, renewal, resubmission, and revision applications. Under this new cycle, the scientific merit review is scheduled for June 2027, followed by an advisory council review in August 2027, with an earliest start date of December 2027. The expiration date for this specific window is January 12, 2027. All other terms and conditions of the original notice of funding opportunity remain unchanged.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

about 1 month ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed)
Solicitation # PAR-28-057
The National Cancer Institute is soliciting applications under solicitation PAR-28-057 to establish the Management and Data Coordination Unit as a key scientific component of the Pancreatic Cancer Detection Consortium. This initiative focuses on the early detection of pancreatic ductal adenocarcinoma and the characterization of precursor lesions to identify high-risk patients, aligning with the NCI's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma. The selected unit will be responsible for providing critical infrastructure and collaborative support, including study design, protocol development, statistical analysis, and comprehensive data management. Additionally, the unit will oversee the coordination of biorepository building and provide the necessary organizational and logistics support to ensure the successful operation of the consortium. Applications must be submitted by the deadline of May 26, 2027.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

about 2 months ago

DEADLINE

in 7 months
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS